首页    期刊浏览 2024年12月01日 星期日
登录注册

文章基本信息

  • 标题:Ezetimibe therapy: mechanism of action and clinical update
  • 本地全文:下载
  • 作者:Binh An P Phan ; Thomas D Dayspring ; Peter P Toth
  • 期刊名称:Vascular Health and Risk Management
  • 印刷版ISSN:1176-6344
  • 电子版ISSN:1178-2048
  • 出版年度:2012
  • 卷号:8
  • 页码:415-427
  • DOI:10.2147/VHRM.S33664
  • 出版社:Dove Medical Press Ltd
  • 摘要:The lowering of low-density lipoprotein cholesterol (LDL-C) is the primary target of therapy in the primary and secondary prevention of cardiovascular events. Although statin therapy is the mainstay for LDL-C lowering, a significant percentage of patients prescribed these agents either do not achieve targets with statin therapy alone or have partial or complete intolerance to them. For such patients, the use of adjuvant therapy capable of providing incremental LDL-C reduction is advised. One such agent is ezetimibe, a cholesterol absorption inhibitor that targets uptake at the jejunal enterocyte brush border. Its primary target of action is the cholesterol transport protein Nieman Pick C1 like 1 protein. Ezetimibe is an effective LDL-C lowering agent and is safe and well tolerated. In response to significant controversy surrounding the use and therapeutic effectiveness of this drug, we provide an update on the biochemical mechanism of action for ezetimibe, its safety and efficacy, as well as the results of recent randomized studies that support its use in a variety of clinical scenarios.
  • 关键词:bile; coronary artery disease; ezetimibe; low-density lipoprotein cholesterol; Nieman pick C1 like 1 protein; statin
国家哲学社会科学文献中心版权所有